Seeking Alpha

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company...

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company has a number of under-appreciated opportunities related to its HIV combination treatments. Oppenheimer therefore reckons Gilead will generate more money from those medicines than expected.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|